0001209191-20-054350.txt : 20201008
0001209191-20-054350.hdr.sgml : 20201008
20201008192059
ACCESSION NUMBER: 0001209191-20-054350
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20201008
FILED AS OF DATE: 20201008
DATE AS OF CHANGE: 20201008
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stampacchia Otello
CENTRAL INDEX KEY: 0001361712
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39592
FILM NUMBER: 201231840
MAIL ADDRESS:
STREET 1: 888 BOYLSTON ST., SUITE 1111
CITY: BOSTON
STATE: MA
ZIP: 02199
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kronos Bio, Inc.
CENTRAL INDEX KEY: 0001741830
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 1300 S. EL CAMINO REAL
STREET 2: SUITE 300
CITY: SAN MATEO
STATE: CA
ZIP: 94402
BUSINESS PHONE: 212-871-7920
MAIL ADDRESS:
STREET 1: 1300 S. EL CAMINO REAL
STREET 2: SUITE 300
CITY: SAN MATEO
STATE: CA
ZIP: 94402
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-10-08
0
0001741830
Kronos Bio, Inc.
KRON
0001361712
Stampacchia Otello
888 BOYLSTON ST.
SUITE 1111
BOSTON
MA
02199
1
0
1
0
Common Stock
19451
I
By Omega Fund V, LP
Series Seed Preferred Stock
Common Stock
1606220
I
By Omega Fund V, LP
Series A Preferred Stock
Common Stock
1376313
I
By Omega Fund V, LP
Convertible Promissory Note
16.15
2022-02-20
Common Stock
366299
I
By Omega Fund V, LP
The reporting person, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega Fund GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). The reporting person may be deemed to share voting and dispositive power over the shares held by Omega L.P. The reporting person, together with Omega GP and Omega Manager, disclaims beneficial ownership of the shares held by Omega L.P. except to the extent of his pecuniary interest therein.
Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") is convertible into 1.055 shares of Common Stock. The Preferred Stock has no expiration date.
The convertible promissory note will automatically convert into shares of the Issuer's common stock upon the closing of the Issuer's first firm commitment underwritten initial public offering.
/s/ David Tanen, Attorney-in-fact
2020-10-08
EX-24.3_940995
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and appoints
each of David Tanen, Yasir Al-Wakeel, Barbara Kosacz and Allison Frisbee of
Kronos Bio, Inc. (the "Company"), signing individually, the undersigned's true
and lawful attorney-in fact and agent to:
(1) execute for and on behalf of the undersigned, an officer, director or holder
of 10% of more of a registered class of securities of the Company, Forms 3, 4
and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934,
as amended (the "Exchange Act") and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute such Form 3, 4 or 5,
complete and execute any amendment or amendments thereto, and timely file such
forms or amendments with the United States Securities and Exchange Commission
and any stock exchange or similar authority; and
(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that each of the foregoing
attorneys-in-fact, in serving in such capacity at the request of the
undersigned, is not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact
shall no longer be employed by the Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 5th day of October 2020.
/s/ Otello Stampacchia, Ph.D.